Valbenazine - Neurocrine Biosciences
Alternative Names: DYSVAL; DYSVAL capsules 40mg; INGREZZA; MT 5199; NBI-98854; REMLEAS; Valbenazine-tosylate; VMAT2-inhibtor-Neurocrine-BiosciencesLatest Information Update: 06 May 2024
At a glance
- Originator Neurocrine Biosciences
- Developer Mitsubishi Tanabe Pharma Corporation; Neurocrine Biosciences
- Class 3-ring heterocyclic compounds; Amino acids; Antipsychotics; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Vesicular monoamine transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chorea; Drug-induced dyskinesia
- Phase III Cerebral palsy; Schizophrenia
- Phase II Gilles de la Tourette's syndrome